A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

M. K. Wallack; K. McNally; M. Michaelides; J. Bash; A. Bartolucci; H. Siegler; C. Balch; H. Wanebo

A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

M. K. Wallack, K. McNally, M. Michaelides, J. Bash, A. Bartolucci, H. Siegler, C. Balch, H. Wanebo

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

Original language	English (US)
Pages (from-to)	148-151
Number of pages	4
Journal	American Surgeon
Volume	52
Issue number	3
State	Published - 1986

ASJC Scopus subject areas

Surgery

Cite this

@article{7d7454a4f2f041e195dc473ed087d353,

title = "A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)",

abstract = "Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.",

author = "Wallack, {M. K.} and K. McNally and M. Michaelides and J. Bash and A. Bartolucci and H. Siegler and C. Balch and H. Wanebo",

year = "1986",

language = "English (US)",

volume = "52",

pages = "148--151",

journal = "American Surgeon",

issn = "0003-1348",

publisher = "Southeastern Surgical Congress",

number = "3",

}

TY - JOUR

T1 - A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

AU - Wallack, M. K.

AU - McNally, K.

AU - Michaelides, M.

AU - Bash, J.

AU - Bartolucci, A.

AU - Siegler, H.

AU - Balch, C.

AU - Wanebo, H.

PY - 1986

Y1 - 1986

N2 - Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

AB - Forty-eight patients with nonrecurrent high risk Stage I and II malignant melanoma were treated with Vaccinia Melanoma Oncolysates (VMO). Six different dose levels and two different treatment regimens were tested. Thirty-two out of 48 patients completed the 12 months of therapy. Side effects were mild to moderate. Twenty-eight out of 48 patients remain free from disease with a mean survival of 19 months, while 20/48 patients have recurred with a mean time to recurrence of 6 months.

UR - http://www.scopus.com/inward/record.url?scp=0022597646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022597646&partnerID=8YFLogxK

M3 - Article

C2 - 3513682

AN - SCOPUS:0022597646

SN - 0003-1348

VL - 52

SP - 148

EP - 151

JO - American Surgeon

JF - American Surgeon

IS - 3

ER -

A Phase I/II SECSG (southeastern cancer study group). Pilot study of surgical adjuvant immunotherapy with Vaccinia Melanoma Oncolysates (VMO)

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this